

Intl. App. No.: PCT/EP02278
Docket No. B45139

Q2
Ans
8. (Amended) An adjuvant composition as claimed in any one of claims 1 [to 7], 2 or 5, comprising a surfactant of formula (1), wherein R is C₈₋₂₀ alkyl or Phenyl C₈₋₂₀ alkyl.

Q3
13. (Amended) An adjuvant composition as claimed in any one of claims 1 [to 12], 2, 5, 9, or 11, comprising a surfactant of formula (1), wherein A is a bond, thereby forming an ether.

14. (Amended) An adjuvant composition as claimed in any one of claims 1 [to 12], 2, 5, 9, or 11, comprising a surfactant of formula (1), wherein A is -C(O)-, thereby forming an ester.

Q4
16. (Amended) An adjuvant composition as claimed in any one of claims 1 [to 15], 2, 5, 9, or 11, wherein the concentration of the surfactant is in the range 0.1-10%.

Q5
19. (Amended) An adjuvant combination, comprising an adjuvant as claimed in any one of claims 1 [to 17], 2, 5, 9, 11, or 18, in combination with at least one additional immunostimulant.

Q6
21. (Amended) An adjuvant composition as claimed in any one of claims 1 [to 20], 2, 5, 9, 11, or 18, further comprising a vehicle, said vehicle comprising of any one of the following group: chitosan or other polycationic polymers, polylaetide and polylactide-co-glycolide particles, particles composed of polysaccharides or chemically modified polysaccharides, or particles composed of glycerol monoesters.

22. (Amended) A vaccine composition comprising an adjuvant composition as claimed in any one of claims 1 [to 21], 2, 5, 9, 11, or 18, further comprising an antigen or antigenic composition.

Q7
24. (Amended) A vaccine as claimed in claim 22 [or 23] wherein the vaccine is in the form of an aerosol or spray.

Q8
32. (Amended) A method of treating a mammal suffering from or susceptible to a pathogenic infection, or cancer, or allergy, comprising the administration of a safe and effective amount of a vaccine composition according to [any of claims 22 to 24] claim 22 to the mammal.